Danés, principal investigator of the Cancer and Stem Cell Biology Lab at the Champalimaud Foundation, in Lisbon, has shown ...

UC San Diego researchers have identified the molecular and cellular mechanisms that transform healthy stem cells into oral ...

The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue ... refined model of KRAS activation informed by ...

Genetics is key to the development of cancer and also in the progression. Some inherited mutations confer a susceptibility to ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $30.00.

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

In addressing this issue, we have shown that the proto-oncogene Jun/AP-1 can function as a potent regulator of the hormone-activated glucocorticoid receptors. "Furthermore, we have demonstrated that ...